{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T10:57:26Z","timestamp":1770461846567,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014480","name":"Horizon Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.dsx.2022.102633","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T12:41:12Z","timestamp":1664455272000},"page":"102633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of empagliflozin in people with type 2 diabetes during Ramadan fasting"],"prefix":"10.1016","volume":"16","author":[{"given":"Sanobia","family":"Yousuf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0493-484X","authenticated-orcid":false,"given":"Muhammad Yakoob","family":"Ahmedani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2022.102633_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.624423","article-title":"Impact of Ramadan diurnal intermittent fasting on hypoglycemic events in patients with type 2 diabetes: a systematic review of randomized controlled trials and observational studies","volume":"12","author":"Abdelrahim","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.dsx.2022.102633_bib2","unstructured":"Surat Al-Baqarah, 2:185."},{"key":"10.1016\/j.dsx.2022.102633_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40200-016-0272-4","article-title":"A\u00a0prospective multi-country observational trial to compare the incidences of diabetic ketoacidosis in the month of Ramadan, the preceding month, and the following month (DKAR international)","volume":"15","author":"Abdelgadir","year":"2016","journal-title":"J\u00a0Diabetes Metab Disord"},{"key":"10.1016\/j.dsx.2022.102633_bib4","first-page":"I26","article-title":"Diabetes and Ramadan: practical guidelines international diabetes federation (IDF) in collaboration with the diabetes and Ramadan (DAR) international alliance","volume":"2016","author":"Hassanein","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2022.102633_bib5","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.2337\/diacare.27.10.2306","article-title":"A\u00a0population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422\/2001 (EPIDIAR) study","author":"Salti","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2022.102633_bib6","doi-asserted-by":"crossref","unstructured":"Babineaux SM, Toaima D, Boye KS, et\u00a0al. multi-country retrospective observational study of the management and outcomes of patients with type 2 diabetes during Ramadan in 2010 (CREED). Diabet Med; 32(6):819-828.","DOI":"10.1111\/dme.12685"},{"issue":"10","key":"10.1016\/j.dsx.2022.102633_bib7","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/dom.12733","article-title":"Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA -Ramadan): a randomized trial","volume":"18","author":"Azar","year":"2016","journal-title":"Diabetes Obes Metabol"},{"issue":"7","key":"10.1016\/j.dsx.2022.102633_bib8","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/dom.12462","article-title":"Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis","volume":"17","author":"Gray","year":"2015","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.dsx.2022.102633_bib9","first-page":"319","article-title":"A\u00a0double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEAD FAST study","volume":"10","author":"Hassanein","year":"2014","journal-title":"Vasc Health Risk Manag"},{"issue":"4","key":"10.1016\/j.dsx.2022.102633_bib10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.4103\/2230-8210.97994","article-title":"Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan","volume":"16","author":"Bashir","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.dsx.2022.102633_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109185","article-title":"Diabetes and Ramadan: practical guidelines 2021","volume":"185","author":"Hassanein","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.dsx.2022.102633_bib12","doi-asserted-by":"crossref","unstructured":"Pathan MF, Sahay RK, Zargar AH, et\u00a0al. South asian consensus guideline: use of insulin in diabetes during Ramadan. Indian J Endocrinol Metab;16(4):499-502..","DOI":"10.4103\/2230-8210.97992"},{"issue":"7","key":"10.1016\/j.dsx.2022.102633_bib13","first-page":"32","article-title":"Options for controlling type 2 diabetes during Ramadan","volume":"18","author":"Almalki","year":"2016","journal-title":"Front Endocrinol"},{"issue":"11","key":"10.1016\/j.dsx.2022.102633_bib14","first-page":"1094","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.dsx.2022.102633_bib15","first-page":"451","article-title":"Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview","volume":"40","author":"Mosley","year":"2015","journal-title":"P\u00a0T"},{"issue":"8","key":"10.1016\/j.dsx.2022.102633_bib16","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2337\/dc18-0588","article-title":"SGLT2 Inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management","volume":"41","author":"van Baar","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2022.102633_bib17","first-page":"109-119","article-title":"Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan","volume":"5","author":"Almaatouq","year":"2012","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.dsx.2022.102633_bib18","doi-asserted-by":"crossref","first-page":"628-632","DOI":"10.1111\/dom.12649","article-title":"Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia","volume":"18","author":"Wan Seman","year":"2016","journal-title":"Diabetes Obes Metabol"},{"issue":"10","key":"10.1016\/j.dsx.2022.102633_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.12991","article-title":"Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: results of the Canagliflozin in Ramadan tolerance observational study (CRATOS)","volume":"71","author":"Hassanein","year":"2017","journal-title":"Int J Clin Pract"},{"issue":"5","key":"10.1016\/j.dsx.2022.102633_bib20","first-page":"389","article-title":"Safety and tolerability of sodium glucose Co-transporter-2 inhibitors (SGLT2i) during Ramadan fasting","volume":"10","author":"Eid","year":"2021","journal-title":"Clin Diabetol"},{"key":"10.1016\/j.dsx.2022.102633_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.diabres.2018.05.022","article-title":"The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes","volume":"142","author":"Shao","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.dsx.2022.102633_bib22","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1016\/j.dsx.2019.07.055","article-title":"Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high-risk insulin treated patients with type 2 diabetes","volume":"13","author":"Abdelgadir","year":"2019","journal-title":"Diabetes Metabol Syndr"},{"issue":"12","key":"10.1016\/j.dsx.2022.102633_bib23","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/jch.12425","article-title":"Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus","volume":"16","author":"Weir","year":"2014","journal-title":"J\u00a0Clin Hypertens"},{"key":"10.1016\/j.dsx.2022.102633_bib24","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.2147\/DDDT.S69926","article-title":"Empagliflozin in the treatment of type 2 diabetes: evidence to date","volume":"9","author":"Shubrook","year":"2015","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.dsx.2022.102633_bib25","doi-asserted-by":"crossref","first-page":"16-34","DOI":"10.3810\/pgm.2014.05.2753","article-title":"Safety and tolerability of canagliflozin in patients with type 2 diabetes: pooled analysis of phase 3 study results","volume":"126","author":"Usiskin","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1016\/j.dsx.2022.102633_bib26","doi-asserted-by":"crossref","first-page":"553-562","DOI":"10.1080\/03007995.2016.1271780","article-title":"Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis","volume":"33","author":"Qiu","year":"2017","journal-title":"Curr Med Res Opin"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122002478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402122002478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:20:23Z","timestamp":1761729623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402122002478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1871402122002478"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102633","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of empagliflozin in people with type 2 diabetes during Ramadan fasting","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2022.102633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd on behalf of Diabetes India.","name":"copyright","label":"Copyright"}],"article-number":"102633"}}